Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2017; 12(7): e0180742.
Published online 2017 July 12. doi:  10.1371/journal.pone.0180742
PMCID: PMC5507541

Protective effect of Galectin-9 in murine model of lung emphysema: Involvement of neutrophil migration and MMP-9 production

Paul Proost, Editor



Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow obstruction and pulmonary emphysema. Persistent inflammation and remodeling of the lungs and airways result in reduced lung function and a lower quality of life. Galectin (Gal)-9 plays a crucial role as an immune modulator in various diseases. However, its role in the pathogenesis of pulmonary emphysema is unknown. This study investigates whether Gal-9 is involved in pulmonary inflammation and changes in emphysema in a porcine pancreatic elastase (PPE)-induced emphysema model.

Materials and methods

Gal-9 was administered to mice subcutaneously once daily from 1 day before PPE instillation to day 5. During the development of emphysema, lung tissue and bronchoalveolar lavage fluid (BALF) were collected. Histological and cytological findings, concentrations of chemokines and matrix metalloproteinases (MMPs) in the BALF, and the influence of Gal-9 treatment on neutrophils were analyzed.


Gal-9 suppressed the pathological changes of PPE-induced emphysema. The mean linear intercept (Lm) of Gal-9-treated emphysema mice was significantly lower than that of PBS-treated emphysema mice (66.1 ± 3.3 μm vs. 118.8 ± 14.8 μm, respectively; p < 0.01). Gal-9 decreased the number of neutrophils and levels of MMP-9, MMP-2 and tissue inhibitor of metalloproteinases (TIMP)-1 in the BALF. The number of neutrophils in the BALF correlated significantly with MMPs levels. Interestingly, Gal-9 pretreatment in vitro inhibited the chemotactic activity of neutrophils and MMP-9 production from neutrophils. Furthermore, in Gal-9-deficient mice, PPE-induced emphysema progressed significantly compared with that in wild–type (WT) mice (108.7 ± 6.58 μm vs. 77.19 ± 6.97 μm, respectively; p < 0.01).


These results suggest that Gal-9 protects PPE-induced inflammation and emphysema by inhibiting the infiltration of neutrophils and decreasing MMPs levels. Exogenous Gal-9 could be a potential therapeutic agent for COPD.


Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of death in the world [1], and its prevalence and mortality rates are steadily increasing. Therefore, COPD is a serious health problem. Even though COPD occurs predominantly in smokers, the fact that only 15%–20% of smokers develop COPD suggests an interaction between genetic, environmental, and other factors in the etiology of COPD [24].

Emphysema, a major component of COPD, is defined as the abnormal enlargement of airspaces distal to the terminal bronchioles accompanied by the irreversible destruction of alveolar walls. COPD is associated with infiltrations of variable inflammatory cells including neutrophils, alveolar macrophages, and CD4+ and CD8+ lymphocytes [59]. The recruitment and activation of neutrophils in the lungs is particularly associated with the pathogenesis of emphysema. In addition, an imbalance in the protease–antiprotease system has long been thought to involve the destruction of alveolar walls and permanent enlargement of air spaces, resulting in emphysema [10]. Current experimental evidence shows that proteases including matrix metalloproteinase-9 (MMP-9) released from activated neutrophils and macrophages digested elastin and other structural proteins, therefore damaging alveolar units [6, 11] [9]. A recent study demonstrated that plasma levels of MMPs are associated with disease severity and are useful as biomarkers in COPD patients [12].

Based on the underlying pathophysiological mechanisms of emphysema, several potential therapeutic approaches targeting the chronic inflammation and subsequent repair have been discussed [13]. Indeed, new strategies for the treatment of COPD focus on the development of anti-inflammatory drugs, including antagonists of cytokines such as tumor necrosis factor (TNF)-α [14] and interleukin (IL)-8 [15]. However, the results of these clinical trials have been disappointing, and thus current treatments are still aimed at temporal symptomatic relief.

Gal-9 belongs to a family of 15 galectins that are characterized by their conserved carbohydrate recognition domains and their affinity for mammalian beta-galactoside [16]. Initially, Gal-9 was identified as an apoptosis inducer for thymocytes [17] and an eosinophil chemoattractant [18], playing important roles in the innate and adaptive immune responses [19]. Gal-9 is emerging as a potent immune regulator in a variety of pathological processes, including inflammation, autoimmunity, fibrosis, and cancer [20]. A recent study showed that Gal-9 down-regulates helper T type 1 (Th1) and Th17 cells responses and is related to suppression mediated by CD4+ CD25+ regulatory T (Treg) cells, mainly via interaction with the T cell immunoglobulin and domain-containing molecule 3 (Tim-3), in murine autoimmune disease models such as collagen-induced arthritis, autoimmune diabetes, and experimental autoimmune encephalomyelitis [16, 2123]. In addition, our previous study revealed that Gal-9 regulates immune responses by expanding myeloid suppressor cells [24] and plasmacytoid dendritic cell (pDC)-like macrophages in a hypersensitivity pneumonitis mouse model and in an acute lung injury mouse model [25, 26]. However, no studies have addressed the effects of Gal-9 on an emphysema model. In the present study, we hypothesized that Gal-9 inhibits lung inflammation and attenuates emphysema in an elastase-induced emphysema model.

Some of the results of this study have been previously reported in the form of abstracts [27].

Materials and methods


Female C57BL/6 mice (8–10 weeks old) were obtained from Charles River Laboratories Japan (Yokohama, Japan). Gal-9–deficient (Gal-9 knock out (KO)) mice were kindly provided by GalPharma (Takamatsu, Japan). The animals were kept under specific pathogen-free conditions. In breeding rooms, we maintained a 12-hr cycle light -dark under constant temperature and humidity. All experimental protocols were approved by the Kumamoto University Animal Care and Use Committee.

Administrations of elastase and Gal-9

All mice were anesthetized intraperitoneally (i.p.) using 0.3 mg/kg of medetomidine, 4.0 mg/kg of midazolam, and 5.0 mg/kg of butorphanol. Mouse lungs were intratracheally instilled with two units of PPE (Elastin Products, Owensville, MO) diluted in 50 μL of saline via a 24-gauge catheter on day 0. The mice were subcutaneously administered either Gal-9 (3 μg/animal) or phosphate-buffered saline (PBS) as a control, once daily for 7 days starting 1 day before PPE instillation through to day 5. Gal-9 was obtained as a recombinant human stable form according to a method described previously [28].

Bronchoalveolar lavage and histological analysis

To obtain bronchoalveolar lavage fluid (BALF) from each group, mice were sacrificed by an overdose of anesthesia on 1, 3, 7, and 14 days after PPE inoculation. BAL was performed using a total 3 mL of PBS (3 × 1 mL). The fluid was then centrifuged at 800 × g for 5 min at 4°C and resuspended in PBS, and the cleared supernatant was collected and stored at −80°C for subsequent analyses. Total cell numbers in BALF were counted using a hemocytometer and an optimal microscope at 400× magnification. After lysating the erythrocytes, cytospin slides of BAL cells were prepared using a cytospin cytocentrifuge (Shandon Cytospin 4 Cytocentrifuge, Thermo Fisher Scientific Inc., Waltham, MA), stained with Diff-Quick solution (Sysmex), and differential cell counts were determined on at least 200 cells depend on standard morphologic criteria.

For histological analysis of lung emphysema, mice were sacrificed on day 21. The lungs were harvested in blocks, inflated by 4% buffered formalin at a constant pressure of 25 cm H2O, and embedded in paraffin. Histological sections (3-μm thickness) were cut for morphometric analysis. A section of lung from each group was stained with hematoxylin and eosin (H&E) [29].

The mean linear intercept (Lm) is widely accepted as an indicator of the presence of emphysema, which means the size of air space. Lm and alveoli number were calculated as previously described [30]. In brief, Lm was measured by dividing the total length of line drawn across the 20 randomly selected lung fields by number of intercepts that the lines with alveolar septum at 200× magnification. Alveoli number was determined by the number of measurements made for the Lm.

Measuring cytokines and matrix metalloproteinases

To measure levels of cytokines and matrixmetalloproteinases (MMPs), the concentrations of keratinocyte-derived cytokine (KC), macrophage inflammatory protein-2 (MIP-2), lipopolysaccharide (LPS)-induced CXC chemokine (LIX), which are murine neutrophil chemoattractants, MMP-9, MMP-2 and tissue inhibitor of metalloproteinases (TIMP)-1 in BALF were determined by enzyme-linked immunosorbent assay (ELISA) using cytokine-specific kits (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions.

Assay for chemotactic activity

Neutrophil chemotaxis was examined using a 48-well chemotaxis chamber (Neuro Probe, Gaithersburg, MD) with a polyvynilpyrrolidone-free 3-μm nucleopore filter as described [25]. To isolate neutrophils for the assay of chemotactic activity, mice were injected i.p. with 3 mL of sterile 3% Brewer Thioglycollate medium [31]. Five hours later, cells were harvested by peritoneal lavage. This procedure routinely yielded 20-million total cells when pooled, with 97% of the cells as neutrophils. Neutrophils were suspended in Ca2+- and Mg2+-free Hanks’ balanced salt solution (HBSS) and preincubated with 1–100 nM Gal-9 or PBS for 4 h [32]. Thereafter, the treated neutrophils were centrifuged at 800 × g for 8 min and washed with HBSS. The neutrophils (5 × 104 cells/well) were pre-incubated with HBSS and then placed in the upper chemotaxis chamber and the medium containing either KC (20 ng/mL) (R&D Systems, Minneapolis, MN) or PBS was poured into the lower chamber. To inhibit the effect of Gal-9, neutrophils were pre-incubated with both 1–100 nM Gal-9 and 5 nM lactose, a representative beta-galactoside, or PBS for 4 h, and the chemotactic activity was examined.

The chamber was incubated at 37°C in a 5% CO2-containing atmosphere for 1 h. When the incubation period was complete, the filter was carefully removed. Neutrophils that did not migrate were wiped off the upper surface of the filter against a rubber blade (Neuro Probe). The remaining neutrophils on filter were counted after Diff-Quick staining as previously reported [25]. Chemotactic activity was expressed as the number of migrated neutrophils per high-powered field magnified at 400×.

MMP-9 production of neutrophils obtained from Gal-9-treated mice

To investigate the effect of Gal-9 in MMP-9 secretion by neutrophils, C57BL/6 mice were subcutaneously administered either Gal-9 (3 μg/animal) or PBS as a control at 0h and 24h, then mice were injected i.p. with 3 mL of sterile 3% Brewer Thioglycollate medium to induce neutrophils. Five hours later, cells were harvested by peritoneal lavage. The neutrophils were washed and resuspended in RPMI-1640 medium. Then a total 1.0 × 106 neutrophils in 1mL were incubated in 24-well plates at 37°C in a 5% CO2-containing atmosphere for 1 h. After incubation, neutrophils were centrifuged for at 800 × g for 5 min and the supernatant was collected for the measurement of MMP-9 by ELISA.

Statistical analysis

Data are presented as the mean ± standard of the mean (SEM). Statistical analyses were performed by one-way ANOVA, followed by post-hoc analysis with the Tukey-Kramer test and Mann-Whitney test. Correlations between variables were assessed using nonparametric two tailed Spearman rank correlation coefficients. A p value of less than 0.05 was used as a threshold for statistical significance. All statistical analyses were performed using Prism 5 software (GraphPad Software, San Diego, CA).


Gal-9 attenuates the PPE-induced emphysema

Gal-9 attenuated the emphysema induced by PPE. Histological analysis on day 21 revealed that PPE-treated mice that were administered PBS (PPE-treated control mice) showed diffuse emphysema lesions, as indicated by alveolar wall destruction and marked enlargement of airspace compared with saline-treated mice (non-PPE-treated mice), but Gal-9 administration did not affect lung structure in non-PPE-treated mice (Fig 1A–1C). The mean linear intercept (Lm) was markedly increased in PPE-treated control mice (118.8 ± 14.8 μm; n = 6) as compared to the non-PPE-treated mice (39.56 ± 2.85 μm; n = 5). By contrast, PPE-treated mice with exogenously added Gal-9 showed significant inhibition of emphysema (Fig 1D) and a significantly smaller Lm (66.07 ± 3.27 μm; n = 10) than that of PPE-treated control mice, with a significant increase in alveoli number (Fig 1E).

Fig 1
Gal-9 attenuates pulmonary emphysema induced by PPE.

Gal-9 prevents PPE-induced neutrophil and lymphocyte infiltrations in BALF

PPE-treated mice showed marked leukocyte infiltration into the bronchoalveolar space preceding the development of emphysema. As shown in Fig 2, the total number of BAL cells transiently increased on day 7 and returned to basal levels on day 14 (Fig 2A). Differential cell analyses showed that the numbers of neutrophils and lymphocytes markedly increased on day 7, and the exogenous administration of Gal-9 in the PPE-induced emphysema model resulted in a striking decrease in the number of total cells, neutrophils, and lymphocytes, with a 54.5%, 74.3%, and 78.2% reduction, respectively, compared to controls (Fig 2A, 2B and 2D). There were no significant differences in the number of macrophages between the experimental groups (Fig 2C) and eosinophils were not detected in both experimental groups.

Fig 2
Gal-9 prevents PPE-induced neutrophil and lymphocyte inflammation in BALF.

Gal-9 reduces MMP-9, MMP-2 and TIMP-1 but not chemokines in BALF

To assess the impact of exogenous Gal-9 administration on MMPs and TIMP-1 production, the levels of MMP-9, MMP-2 and TIMP-1 in BALF were compared between the Gal-9-treated and control mice. Gal-9 significantly reduced MMP-9, MMP-2 and TIMP-1 levels in BALF on day 7 in the emphysema model (Fig 3A–3C). To further investigate the influence on the expression of chemokine for neutrophils, we measured levels of KC, MIP-2, and LIX in the BALF on day 7. No differences in the levels of these chemokines were observed between the experimental groups (Fig 3D–3F). These results suggest that Gal-9 attenuates PPE-induced emphysema by suppressing neutrophil recruitment and MMP-9 and MMP-2 production but does not reduce the levels of chemoattractants for neutrophils.

Fig 3
Gal-9 treatment decreases levels of MMP-9, MMP-2 and TIMP-1 but not neutrophil chemoattractants in BALF.

Interestingly, the MMP-9, MMP-2 and TIMP-1 levels in BALF correlated significantly with the number of neutrophils (rs = 0.6495; p = 0.0048, rs = 0.7000; p = 0.0433, rs = 0.7059; p = 0.0369, respectively) (Fig 4A–4C) but not the number of lymphocytes (rs = -0.02457; p = 0.9254, rs = 0.5500; p = 0.1328, rs = 0.4622; p = 0.2125, respectively) (Fig 4D–4F).

Fig 4
Numbers of neutrophils correlates with MMP-9, MMP-2 and TIMP-1 levels in BALF.

Gal-9 inhibits chemotaxis of neutrophils in vitro

Because Gal-9 appeared to modulate neutrophil recruitment rather than inhibiting chemokine production, we examined whether Gal-9 directly inhibits the chemotactic activity of neutrophils toward the chemokine KC. Gal-9 had no effect on cell viability as confirmed by trypan blue staining. The chemotactic activity of Gal-9–preincubated neutrophils was significantly decreased, and the effect was reversed by the addition of lactose to Gal-9 (Fig 5). These results suggested that Gal-9 directly suppresses KC-induced neutrophil chemotaxis.

Fig 5
Gal-9 inhibits neutrophil chemotaxis, an effect that is reversed by the addition of lactose.

Gal-9 inhibits the MMP-9 secretion from neutrophils

To investigate the effect of Gal-9 in MMP-9 secretion from neutrophils, the neutrophils obtained from PBS-treated mice or Gal-9-treated mice was cultured in vitro for 1 h. The level of MMP-9 in culture supernatant of neutrophils obtained from Gal-9-treated mice were significantly lower than that from PBS-treated mice (Fig 6). These results suggest that Gal-9 inhibits the MMP-9 secretion from neutrophils and reduction of MMP-9 itself might affect the migration of neutrophils.

Fig 6
Gal-9 inhibits the MMP-9 secretion from neutrophils.

PPE-induced emphysema is exacerbated in Gal-9-deficient mice

Previous research has demonstrated that Gal-9 in the lung maintains cell and tissue homeostasis under physiological conditions and after inflammatory responses [33]. To clarify whether endogenous Gal-9 has protective effects on the development of emphysema, we examined the histological and cellular changes of PPE-induced emphysema in Gal-9-deficient mice.

At day 21 of PPE administration, air space enlargements and alveolar wall destruction were more severe in Gal-9-deficient mice than in WT mice (Fig 7A and 7B). Lm values for Gal-9-deficient mice (108.7 ± 6.58 μm; n = 5) were significantly increased compared to WT mice (77.19 ± 6.97 μm; n = 5) 21 days after treatment with PPE (Fig 7C). The number of total cells and neutrophils in BALF on day 7 was higher in Gal-9-deficient than in WT mice, although this difference was not statistically significant. In contrast, the number of lymphocytes and macrophages were not different (Fig 7D). The levels of MMP-9, MMP-2 and TIMP-1 did not differ between WT mice and Gal-9-deficient mice 7 days after PPE treatment (Fig 7E). These histological and cellular evaluations demonstrate that Gal-9-deficient mice are more susceptible to PPE-induced changes in the lung and that endogenously-released Gal-9 has inhibitory effects on PPE-induced emphysema.

Fig 7
PPE-induced lung emphysema is exacerbated in Gal-9–deficient mice.


In this study, we addressed the contribution of Gal-9 to the pathogenesis of emphysema. We found that Gal-9 attenuated PPE-induced emphysema in a murine model by inhibiting the infiltration of neutrophils and MMP-9 production in the lung. Gal-9 treatment inhibited the neutrophil chemotaxis in response to chemoattractant. In Gal-9 deficient mice, PPE-induced pulmonary emphysema was exacerbated by the enhanced neutrophil recruitment in the lung.

COPD is a major worldwide public health concern as it leads to a slowly-progressive deterioration in pulmonary function, substantial morbidity, and increased mortality [1]. One of the current accepted hypotheses regarding the pathogenesis of cigarette-smoke-induced emphysema is the involvement of a protease–antiprotease imbalance. Based on this hypothesis, experimental emphysema mice models were designed by the administration of elastolytic enzymes, such as PPE, either by intratracheal instillation or aerosol inhalation [34, 35]. The PPE-induced emphysema models have been used in studies for more than 40 years [36] to reproduce some of the characteristics of cigarette-smoke-induced disease in humans, such as enlargement of air spaces, inflammatory cell influx into the lung, and systemic inflammation [37]. Using this model, several studies have developed new pharmacological strategies for attenuating the inflammation or remodeling processes. Although implicated in health and disease, a detailed understanding of the involvement of galectins in pulmonary emphysema is lacking. In the present study, we demonstrated that treatment with Gal-9 attenuates PPE-induced emphysema (Fig 1).

Gal-9-treated animals had lower numbers of total cells, neutrophils, lymphocytes in BALF (Fig 2A, 2B and 2D), suggesting that Gal-9 had an important anti-inflammatory effect in this model. Gal-9 effectively reduced the cell fraction of neutrophils in BALF from 69% to 35%. One of the pathogenesis of emphysema and COPD is pulmonary inflammation, and neutrophil recruitment into the lung is thought to play a central role in its development. Additionally, previous data in animal models have indicated a strong relationship between inflammation and emphysematous changes [38].

The anti-inflammatory effects of Gal-9 in the lung were previously reported in the hypersensitivity pneumonitis mouse model [24] and LPS-induced acute lung injury model that we reported [25]. Most reports show that Gal-9 has effects reducing the levels of pro-inflammatory cytokines and chemotactic factors interferon-γ (IFN-γ), IL-1β, IL-17, IL-6, KC, TNF-α, and monocyte chemoattractant protein-1 (MCP-1) in the lung. Even though KC, MIP-2, and LIX are the main signaling molecules in the recruitment of neutrophils and macrophages, Gal-9 did not reduce their levels in BALF during the process of emphysema formation (Fig 3D–3F). In this PPE-induced emphysema model, the levels of chemokines in BALF were not elevated as compared to other acute inflammatory mice models [16], including our LPS-induced acute lung injury model [25]. One reason for this lack of change in chemokine expression is that the functions of chemokine-producing cells such as macrophages and endothelial cells are likely to be modulated by the administration of Gal-9. Arikawa et al. reported that treatment with Gal-9 in an arthritis model repressed macrophage activity, resulting in a significant reduction in proinflammatory cytokine expression and up-regulation of the anti-inflammatory cytokine IL-10 [39]. They also showed that the number of CD11b+Ly-6Chigh immunosuppressive macrophages was increased by treatment with Gal-9 in experimental lung inflammation [24].

Similarly, our previous study using a mouse model of acute lung injury demonstrated that Gal-9 treatment increased the number of CD14- plasmacytoid dendritic cell-like macrophages and suppressed the accumulation of neutrophils in the lung by decreasing macrophage-derived chemokines and neutrophil-activating pro-inflammatory cytokines [25]. Therefore, in the present study, we examined the influence of these suppressor macrophages in a Gal-9–treated emphysema model. However, the number of these cells present in BALF were unaffected by exogenously added Gal-9 (data not shown). Further studies are required to more directly address the anti-inflammatory effects of Gal-9 during emphysema pathogenesis.

We examined whether Gal-9 inhibits the migration of neutrophils in response to chemotactic stimulation with KC. In our in vitro study, Gal-9 treatment significantly reduced the chemotactic activity of neutrophils, and the effect was reversed by lactose, a representative beta-galactoside (Fig 5). Thus, the inhibition of chemotaxis by Gal-9 may be dependent on its carbohydrate moieties and seems to involve direct interaction between Gal-9 and neutrophils. However, this finding seems to conflict with previous findings indicating the role of Gal-9 as an activator of neutrophils [40][41]. Steichen et al. demonstrated that Gal-9 induces the production of inflammatory mediators by neutrophils in a bacterial septic model and that the survival of the Gal-9 blockade was significantly greater than in WT mice [40]. Moreover, a recent study showed that Gal-9 directly binds to TIM-3 on neutrophils and up-regulates neutrophil functions including phagocytosis, protease degranulation, and inflammatory infiltration [41]. Conversely, the mechanism underlying the inhibitory effect of Gal-9 on neutrophil migration is not fully understood. This inhibition of chemotaxis by Gal-9 is similar to that observed by Gal-1 and -3, which also inhibit chemotaxis and the transendothelial migration of neutrophils [42, 43]. The effects of galectins are complex and vary depending on the local concentration, differentiation status of the target cells, and the type of inflammatory condition [33]. Further studies are required to determine the precise underlying mechanisms.

In the present study, Gal-9 was observed to decrease the levels of MMP-9, MMP-2 and TIMP-1 in BALF (Fig 3A–3C). In an animal model of emphysema and in patients with COPD, several MMPs, including MMP-9, are elevated in sputum, BALF, and lung tissue specimens [2, 30, 44, 45] and are related to poor lung function. MMP inhibition attenuates emphysema and small-airway remodeling in guinea pigs and hamsters [46, 47]. However, D’Armiento et al. found no significant correlation between MMP-9 and emphysema severity [48]. Zheng et al. reported that MMP-2 might also be important in other mouse models of pulmonary emphysema [49]. But together with MMP-9, MMP-2 degrades elastin and type IV collagen, the major component of lung structures. MMP-2 also may affect the induction of emphysema and alveolar wall damage. Gal-9 expression is regulated by MMPs other than MMP-2 and -9, and Gal-9 contains MMP cleavage sites [50] Although little is known about the involvement of Gal-9 in MMP-9 expression, one study revealed that infected Gal-9–deficient mice displayed significantly reduced levels of MMP-9 in lung extracts and accompanying decreases in neutrophil infiltration and inflammatory mediators [40]. In the present study, exogenous administration of Gal-9 in an emphysema animal model reduced the levels of MMP-9, MMP-2 and TIMP-1 in BALF (Fig 3A–3C), and these MMPs levels correlated significantly with the number of neutrophils in BALF (Fig 4A–4C). Neutrophils are a major source of MMP-9 in inflamed lung [51]. Therefore, we suggest that the decrease in MMP-9, MMP-2 in BALF may result from the reduced number of neutrophils in BALF induced by Gal-9. Gal-9 reduced the level of MMP-9 secreted by neutrophils (Fig 6). These data suggested that Gal-9 involved in neutrophil-extracellular matrix interaction via the MMP-9 dependent pathway and regulates cell adhesion at multiple steps in part, both directly and indirectly. Further studies are needed to verify and clarify the role of MMP-9 in Gal-9-mediated activities.

In the present study, PPE-induced emphysema in Gal-9–deficient mice was significantly exacerbated as compared to that in WT mice (Fig 7A–7C). In addition, neutrophil infiltration in BALF in Gal-9-deficient mice was increased, although this difference was not statistically significant (Fig 7D). The levels of MMP-9, MMP-2 and TIMP-1 did not differ between WT and Gal-9-deficient mice 7 days after PPE treatment (Fig 7E). The reason for these gaps is hard to explain. We speculate that large amount of exogenously administered Gal-9 suppressed the migration of neutrophils and secretion of MMP-9 and MMP-2, but not endogenously released Gal-9 in WT mice. These data demonstrate that Gal-9-deficient mice are more susceptible to PPE-induced changes in the lung and that endogenously released Gal-9 has inhibitory effects in part on PPE-induced emphysema.

In conclusion, the present study demonstrates that Gal-9 prevents PPE-induced inflammation and emphysema in mice by inhibiting the infiltration of neutrophils, leading to reduced MMP-9 production. Although the precise mechanisms involved are still unclear, Gal-9-mediated inflammatory responses show beneficial effects in reducing PPE-induced emphysema, suggesting that Gal-9 could be a candidate therapeutic agent for the treatment of pulmonary emphysema and COPD.

Supporting information

S1 Fig

Representative photomicrographs of Diff-Quick stained cytospin slide of BALF.

BAL cells stained with Diff-Quick solution after cytospin. Representative picture are shown on day 7 BALF from PPE (+) Gal-9 (-) (A) and PPE (+) Gal-9 (+) (B) at 400× magnification. Abbreviations: BAL, bronchoalveolar lavage; BALF, bronchoalveolar lavage fluid.



The authors thank Dr. Aiko Masunaga for reviewing the manuscript and Ms. Kanako Ito for technical assistance.

Funding Statement

The authors received no specific funding for this work.

Data Availability

Data Availability

Data are available within the Dryad Digital Repository (doi:10.5061/dryad.f13g4).


1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi: 10.1164/rccm.201204-0596PP . [PubMed]
2. Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med. 2003;97(6):634–639. . [PubMed]
3. He JQ, Ruan J, Connett JE, Anthonisen NR, Pare PD, Sandford AJ. Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Am J Respir Crit Care Med. 2002;166(3):323–328. doi: 10.1164/rccm.2111059 . [PubMed]
4. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(2):420–422. doi: 10.1164/ajrccm.163.2.2006031 . [PubMed]
5. Ofulue AF, Ko M. Effects of depletion of neutrophils or macrophages on development of cigarette smoke-induced emphysema. Am J Physiol. 1999;277(1 Pt 1):L97–105. . [PubMed]
6. Dhami R, Gilks B, Xie C, Zay K, Wright JL, Churg A. Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. Am J Respir Cell Mol Biol. 2000;22(2):244–252. doi: 10.1165/ajrcmb.22.2.3809 . [PubMed]
7. Smyth LJ, Starkey C, Vestbo J, Singh D. CD4-regulatory cells in COPD patients. Chest. 2007;132(1):156–163. doi: 10.1378/chest.07-0083 . [PubMed]
8. Mikko M, Forsslund H, Cui L, Grunewald J, Wheelock AM, Wahlstrom J, et al. Increased intraepithelial (CD103+) CD8+ T cells in the airways of smokers with and without chronic obstructive pulmonary disease. Immunobiology. 2013;218(2):225–231. doi: 10.1016/j.imbio.2012.04.012 . [PubMed]
9. Cheng SL, Wang HC, Yu CJ, Tsao PN, Carmeliet P, Cheng SJ, et al. Prevention of elastase-induced emphysema in placenta growth factor knock-out mice. Respir Res. 2009;10:115 doi: 10.1186/1465-9921-10-115 . [PMC free article] [PubMed]
10. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653. doi: 10.1056/NEJMoa032158 . [PubMed]
11. Churg A, Zay K, Shay S, Xie C, Shapiro SD, Hendricks R, et al. Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am J Respir Cell Mol Biol. 2002;27(3):368–374. doi: 10.1165/rcmb.4791 . [PubMed]
12. Koo HK, Hong Y, Lim MN, Yim JJ, Kim WJ. Relationship between plasma matrix metalloproteinase levels, pulmonary function, bronchodilator response, and emphysema severity. Int J Chron Obstruct Pulmon Dis. 2016;11:1129–1137. doi: 10.2147/COPD.S103281 . [PMC free article] [PubMed]
13. Seemungal TA, Wedzicha JA. Update in Chronic Obstructive Pulmonary Disease 2014. Am J Respir Crit Care Med. 2015;192(9):1036–1044. doi: 10.1164/rccm.201503-0534UP . [PubMed]
14. Dentener MA, Creutzberg EC, Pennings HJ, Rijkers GT, Mercken E, Wouters EF. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration. 2008;76(3):275–282. doi: 10.1159/000117386 . [PubMed]
15. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004;126(3):926–934. doi: 10.1378/chest.126.3.926 . [PubMed]
16. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127(1):78–88. doi: 10.1016/j.clim.2008.01.006 . [PubMed]
17. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Invest. 1997;99(10):2452–2461. doi: 10.1172/JCI119429 . [PMC free article] [PubMed]
18. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem. 1998;273(27):16976–16984. . [PubMed]
19. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 2009;9(5):338–352. doi: 10.1038/nri2536 . [PubMed]
20. Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 2002;23(6):313–320. . [PubMed]
21. Chou FC, Shieh SJ, Sytwu HK. Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. Eur J Immunol. 2009;39(9):2403–2411. doi: 10.1002/eji.200839177 . [PubMed]
22. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141–1143. doi: 10.1126/science.1148536 . [PubMed]
23. Leskela S, Serrano A, de la Fuente H, Rodriguez-Munoz A, Ramos-Levi A, Sampedro-Nunez M, et al. Graves' disease is associated with a defective expression of the immune regulatory molecule galectin-9 in antigen-presenting dendritic cells. PLoS One. 2015;10(4):e0123938 doi: 10.1371/journal.pone.0123938 . [PMC free article] [PubMed]
24. Arikawa T, Saita N, Oomizu S, Ueno M, Matsukawa A, Katoh S, et al. Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. Eur J Immunol. 2010;40(2):548–558. doi: 10.1002/eji.200939886 . [PubMed]
25. Kojima K, Arikawa T, Saita N, Goto E, Tsumura S, Tanaka R, et al. Galectin-9 attenuates acute lung injury by expanding CD14- plasmacytoid dendritic cell-like macrophages. Am J Respir Crit Care Med. 2011;184(3):328–339. doi: 10.1164/rccm.201010-1566OC . [PubMed]
26. Kadowaki T, Morishita A, Niki T, Hara J, Sato M, Tani J, et al. Galectin-9 prolongs the survival of septic mice by expanding Tim-3-expressing natural killer T cells and PDCA-1+ CD11c+ macrophages. Crit Care. 2013;17(6):R284 doi: 10.1186/cc13147 . [PMC free article] [PubMed]
27. Horio Y, Kojima K, Saita N, Migiyama Y, Masunaga A, Ichiyasu H, et al. Galectin-9 attenuates elastase-induced emphysema by reducing neutrophil chemotaxis in mice [abstract]. ERS International Congress 2016:PA4013; London, United Kingdom.
28. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, et al. Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett. 2005;579(10):2058–2064. doi: 10.1016/j.febslet.2005.02.054 . [PubMed]
29. Taguchi L, Pinheiro NM, Olivo CR, Choqueta-Toledo A, Grecco SS, Lopes FD, et al. A flavanone from Baccharis retusa (Asteraceae) prevents elastase-induced emphysema in mice by regulating NF-kappaB, oxidative stress and metalloproteinases. Respir Res. 2015;16:79 doi: 10.1186/s12931-015-0233-3 . [PMC free article] [PubMed]
30. Dunnill MS. Quantitative methods in the study of pulmonary pathology. Thorax. 1962;17(4):320–328. . [PMC free article] [PubMed]
31. Baron EJ, Proctor RA. Elicitation of peritoneal polymorphonuclear neutrophils from mice. J Immunol Methods. 1982;49(3):305–313. . [PubMed]
32. Tsai WC, Rodriguez ML, Young KS, Deng JC, Thannickal VJ, Tateda K, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med. 2004;170(12):1331–1339. doi: 10.1164/rccm.200402-200OC . [PubMed]
33. John S, Mishra R. Galectin-9: From cell biology to complex disease dynamics. J Biosci. 2016;41(3):507–534. . [PubMed]
34. Wright JL, Cosio M, Churg A. Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2008;295(1):L1–15. doi: 10.1152/ajplung.90200.2008 . [PubMed]
35. Baila B, Ohno Y, Nagamoto H, Kotosai K, Yabuuchi Y, Funaguchi N, et al. Tetomilast attenuates elastase-induced pulmonary emphysema through inhibition of oxidative stress in rabbits. Biol Pharm Bull. 2012;35(4):494–502. . [PubMed]
36. Kaplan PD, Kuhn C, Pierce JA. The induction of emphysema with elastase. I. The evolution of the lesion and the influence of serum. J Lab Clin Med. 1973;82(3):349–356. . [PubMed]
37. Antunes MA, Rocco PR. Elastase-induced pulmonary emphysema: insights from experimental models. An Acad Bras Cienc. 2011;83(4):1385–1396. . [PubMed]
38. Lucey EC, Keane J, Kuang PP, Snider GL, Goldstein RH. Severity of elastase-induced emphysema is decreased in tumor necrosis factor-alpha and interleukin-1beta receptor-deficient mice. Lab Invest. 2002;82(1):79–85. . [PubMed]
39. Arikawa T, Watanabe K, Seki M, Matsukawa A, Oomizu S, Sakata KM, et al. Galectin-9 ameliorates immune complex-induced arthritis by regulating Fc gamma R expression on macrophages. Clin Immunol. 2009;133(3):382–392. doi: 10.1016/j.clim.2009.09.004 . [PubMed]
40. Steichen AL, Simonson TJ, Salmon SL, Metzger DW, Mishra BB, Sharma J. Alarmin function of galectin-9 in murine respiratory tularemia. PLoS One. 2015;10(4):e0123573 doi: 10.1371/journal.pone.0123573 . [PMC free article] [PubMed]
41. Vega-Carrascal I, Bergin DA, McElvaney OJ, McCarthy C, Banville N, Pohl K, et al. Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung. J Immunol. 2014;192(5):2418–2431. doi: 10.4049/jimmunol.1300711 . [PMC free article] [PubMed]
42. La M, Cao TV, Cerchiaro G, Chilton K, Hirabayashi J, Kasai K, et al. A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am J Pathol. 2003;163(4):1505–1515. . [PubMed]
43. Baseras B, Gaida MM, Kahle N, Schuppel AK, Kathrey D, Prior B, et al. Galectin-3 inhibits the chemotaxis of human polymorphonuclear neutrophils in vitro. Immunobiology. 2012;217(1):83–90. doi: 10.1016/j.imbio.2011.07.031 . [PubMed]
44. Prause O, Bozinovski S, Anderson GP, Linden A. Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17 in mouse airways. Thorax. 2004;59(4):313–317. doi: 10.1136/thx.2003.008854 . [PMC free article] [PubMed]
45. Ilumets H, Rytila P, Demedts I, Brusselle GG, Sovijarvi A, Myllarniemi M, et al. Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD. Int J Chron Obstruct Pulmon Dis. 2007;2(3):369–379. . [PMC free article] [PubMed]
46. Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax. 2007;62(8):706–713. doi: 10.1136/thx.2006.068353 . [PMC free article] [PubMed]
47. Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, et al. Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006;49(2):456–458. doi: 10.1021/jm051101g . [PubMed]
48. D'Armiento JM, Goldklang MP, Hardigan AA, Geraghty P, Roth MD, Connett JE, et al. Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. PLoS One. 2013;8(2):e56352 doi: 10.1371/journal.pone.0056352 . [PMC free article] [PubMed]
49. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ Jr., et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106(9):1081–1093. doi: 10.1172/JCI10458 . [PMC free article] [PubMed]
50. Chabot S, Kashio Y, Seki M, Shirato Y, Nakamura K, Nishi N, et al. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology. 2002;12(2):111–118. . [PubMed]
51. Mackarel AJ, Cottell DC, Russell KJ, FitzGerald MX, O'Connor CM. Migration of neutrophils across human pulmonary endothelial cells is not blocked by matrix metalloproteinase or serine protease inhibitors. Am J Respir Cell Mol Biol. 1999;20(6):1209–1219. doi: 10.1165/ajrcmb.20.6.3539 . [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science